{
    "doi": "https://doi.org/10.1182/blood.V122.21.5046.5046",
    "article_title": "Treatment With Leukapheresis In Patients Diagnosed With Hyperleukocytic Acute Myeloid Leukemia ",
    "article_date": "November 15, 2013",
    "session_type": "615. Acute Myeloid Leukemia: Therapy, excluding Transplantation",
    "abstract_text": "Background Patients with hyperleukocytic acute myeloid leukemia (AML) have a high mortality rate during induction treatment. This mortality is mainly due to bleeding complications, tumor lysis syndrome and symptoms of hyperleukocitosis. Although there is no clear evidence of benefit, leukapheresis is indicated to reduce the number of leukocytes (WBC) in peripheral blood and prevent or relieve leukostasis symptoms before starting cytotoxic therapy. Objetives Analyze the characteristics of a series of patients with hyperleukocytic AML who started induction treatment and assess the outcome depending on whether leukapheresis was performed or not. Methods All adult patients with hyperleukocytic AML (WBC> 95 x 109 / L) who received induction therapy in the Hospital La Fe between 1979 and 2012 were included. The leukapheresis was indicated according to physician discretion. The characteristics and mortality of both groups, patients who underwent leukapheresis and non-leukapheresis, were compared. Then a \u201cmatched-paired analysis\u201d was performed according to ECOG, WBC and coagulopathy in a 2:1 ratio to compare results from two homogeneous cohorts. Results One hundred and forty patients diagnosed with hyperleukocytic AML received induction therapy, 18 of them underwent leukapheresis. Patients who underwent leukapheresis compared with non-leukapheresis showed a median age of 55 years (16-71) vs 58 (14-75) and WBC at diagnosis of 198 \u00b4 10 9 / L (101-620) vs 141 (97-375), respectively. The leukapheresis group had a worse ECOG (p = 0.03), more leukocytes (p = .003), more coagulopathy (p = .03), more leukostasis symptoms (p <.001) and more mortality at 7 days (p = .02). From the \u201cmatched-paired analysis\u201d, 2 cohorts were obtained, whose characteristics are shown in Table 1 . After comparing the group of leukapheresis and non-leukapheresis (n = 36), there were no significant differences between them, including leukocyte count, ECOG, coagulopathy and leukostasis. There were also no significant differences in mortality at 7, 14, 21 and 28 days (p = .60, p = .99, p = .92, p = .99, respectively). Table 1 Baseline characteristics and induction mortality in the cohorts  . Leukapheresis \u2003(n=18) . Non-leukapheresis (n=36) . P . Characteristics . Median (range) . n (%) . Median (range) . n (%) . . Age  55 (16-71)  63 (15-75)  .09 Sex       Men  8 (44)  19 (53) .77 Female  10 (56)  17 (47)  ECOG  2 (0-4)  2 (0-4)   0-2  9 (53)  23 (64) .99 3-4  8 (47)  13 (36)  AML type       De novo   17 (94)  33 (92) .53 Secondary  1 (6)  3 (8)  FAB Subtype       M4/M5  6 (33)  16 (44) .30 Non M4/M5  12 (67)  20 (56)  Leukostasis       No  7 (39)  18 (50) .31 Yes  11 (61)  18 (50)  Leukocyte, \u00b410 9 /L  198 <>(101\u2013620)  189 (97-375)  .17 Platelets, \u00b410 9 /L  38 (23\u2013198)  53 (9\u2013148)  .99 Hemoglobin , g/dL  9,1 (3,6-13,4)  9,7 (4,3-14,2)  .17 Coagulopathy       No  7 (39)  16 (44) .92 Yes  11 (61)  20 (56)  ICH at diagnosis       No  16 (89)  32 (89) .99 Yes  2 (11)  4 (11)  AMLtherapy       Triple therapy  3 (17)  9 (22) .76 Antracyclic + Ara-C  10 (55)  19 (53)  Other  5 (28)  8 (25)  Period       1979\u20131990  2 (11)  9 (25) .47 1991\u20132000  6 (33)  9 (25)  2001\u20132012  10 (56)  18 (50)  Mortality       At 7 days  7 (39)  10 (28) .60 At 14 days  7 (39)  15 (42) .99 At 21 days  8 (44)  18 (50) .92 At 28 days  9 (50)  18 (50) .99 . Leukapheresis \u2003(n=18) . Non-leukapheresis (n=36) . P . Characteristics . Median (range) . n (%) . Median (range) . n (%) . . Age  55 (16-71)  63 (15-75)  .09 Sex       Men  8 (44)  19 (53) .77 Female  10 (56)  17 (47)  ECOG  2 (0-4)  2 (0-4)   0-2  9 (53)  23 (64) .99 3-4  8 (47)  13 (36)  AML type       De novo   17 (94)  33 (92) .53 Secondary  1 (6)  3 (8)  FAB Subtype       M4/M5  6 (33)  16 (44) .30 Non M4/M5  12 (67)  20 (56)  Leukostasis       No  7 (39)  18 (50) .31 Yes  11 (61)  18 (50)  Leukocyte, \u00b410 9 /L  198 <>(101\u2013620)  189 (97-375)  .17 Platelets, \u00b410 9 /L  38 (23\u2013198)  53 (9\u2013148)  .99 Hemoglobin , g/dL  9,1 (3,6-13,4)  9,7 (4,3-14,2)  .17 Coagulopathy       No  7 (39)  16 (44) .92 Yes  11 (61)  20 (56)  ICH at diagnosis       No  16 (89)  32 (89) .99 Yes  2 (11)  4 (11)  AMLtherapy       Triple therapy  3 (17)  9 (22) .76 Antracyclic + Ara-C  10 (55)  19 (53)  Other  5 (28)  8 (25)  Period       1979\u20131990  2 (11)  9 (25) .47 1991\u20132000  6 (33)  9 (25)  2001\u20132012  10 (56)  18 (50)  Mortality       At 7 days  7 (39)  10 (28) .60 At 14 days  7 (39)  15 (42) .99 At 21 days  8 (44)  18 (50) .92 At 28 days  9 (50)  18 (50) .99 ICH: intracraneal hemorrhage View Large Conclusions Patients diagnosed with hyperleukocytic AML who underwent leukapheresis showed more leukocytes, leukostasis and coagulopathy. After analizying two comparable groups, leukapheresis failed to reduce mortality. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "leukapheresis",
        "leukemia, myelocytic, acute",
        "blood coagulation disorders",
        "leukostasis",
        "electrocorticogram",
        "hemorrhage",
        "neoadjuvant therapy",
        "cytarabine",
        "cytotoxic drug therapy",
        "hemoglobin"
    ],
    "author_names": [
        "David Mart\u00ednez-Cuadr\u00f3n",
        "Pau Montesinos",
        "Federico Moscardo",
        "Lineth Lopez, MD",
        "Guillermo Martin",
        "Pilar Solves",
        "Blanca Boluda",
        "Mariluz P\u00e9rez-Sirvent",
        "Belen Vera",
        "Ines Navarro",
        "Carmen M Alonso",
        "Jesus Martinez, MD",
        "Francisca L\u00f3pez-Chulia",
        "Jaime Sanz, MD",
        "Nelly Carpio",
        "Rebeca Rodr\u00edguez-Veiga",
        "Gloria Iacoboni",
        "Guillermo Sanz, MD, PhD",
        "Miguel Sanz"
    ],
    "author_dict_list": [
        {
            "author_name": "David Mart\u00ednez-Cuadr\u00f3n",
            "author_affiliations": [
                "Hospital Universitari i politecnic La Fe, PETHEMA cooperative group, Valencia, Spain, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Pau Montesinos",
            "author_affiliations": [
                "Hematology, Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Federico Moscardo",
            "author_affiliations": [
                "Hematology, Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lineth Lopez, MD",
            "author_affiliations": [
                "Hematolog\u00eda, Complejo Hospitalario Metropolitano Dr. Arnulfo Arias Madrid, Panam\u00e1, Panama, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guillermo Martin",
            "author_affiliations": [
                "Hospital Universitario La Fe, Valencia, Spain, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Solves",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Blanca Boluda",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mariluz P\u00e9rez-Sirvent",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Belen Vera",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ines Navarro",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carmen M Alonso",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jesus Martinez, MD",
            "author_affiliations": [
                "Hospital Universitario La Fe, Valencia, Spain, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisca L\u00f3pez-Chulia",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jaime Sanz, MD",
            "author_affiliations": [
                "Hospital Universitario La Fe, Valencia, Spain, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nelly Carpio",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rebeca Rodr\u00edguez-Veiga",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gloria Iacoboni",
            "author_affiliations": [
                "Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guillermo Sanz, MD, PhD",
            "author_affiliations": [
                "Hospital Universitario y Polit\u00e9cnico La Fe Valencia, Valencia, Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel Sanz",
            "author_affiliations": [
                "Hematology, Hospital Universitari i Politecnic La Fe, Valencia, Spain, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T04:09:50",
    "is_scraped": "1"
}